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Introduction
Mice with functional ablation of the substance P-preferring (NK1) 
receptor gene (NK1R-/-) (De Felipe et al., 1998) express several 
abnormal behaviours when compared with their wild types 
(NK1R+/+). These include locomotor hyperactivity, which is 
ameliorated by the psychostimulants, d-amphetamine and methyl-
phenidate (Yan et al., 2010), together with a greater incidence of 
premature responses (a form of impulsivity), % omissions (failure 
to respond in the task, which can indicate inattentiveness) and 
perseveration in the 5-Choice Serial Reaction-Time Task 
(5-CSRTT) (Yan et al., 2011). Hyperactivity, impulsivity and inat-
tentiveness are core features of Attention Deficit Hyperactivity 
Disorder (ADHD) in humans. Perseveration has been reported in 
ADHD patients, but is neither common nor a diagnostic criterion. 
Regulation of dopaminergic, noradrenergic and serotonergic 
transmission in corticostriatal brain regions is also disrupted in 
these mutant mice (Froger et al., 2001; Herpfer et al., 2005; Yan et 
al., 2011), as is thought to be the case in ADHD. Our proposal that 
NK1R-/- mice express the key signs of this disorder is supported 
by evidence for an association between polymorphisms in, or 
near, the TACR1 receptor gene (the human equivalent of the nk1R 
gene) and increased vulnerability to ADHD (Yan et al., 2010).
Acute administration of an NK1R antagonist (either RP 67580 
or L 733060) increases locomotor activity of wild type, but not 
NK1R-/-, mice (Yan et al., 2010), suggesting that the hyperactiv-
ity of NK1R-/- mice is a direct consequence of their lack of 
functional NK1R, rather than any secondary developmental or 
adaptive change in the phenotype. Here, we investigated whether 
deficits in cognitive performance of NK1R-/- mice can similarly 
be attributed to an acute lack of NK1R-mediated transmission. To 
that end, we tested whether treatment with the NK1R antagonists, 
RP 67580 or L 733060, impairs performance of wild type mice in 
the 5-CSRTT, at doses that induce locomotor hyperactivity.
After training wild type and NK1R-/- mice in the 5-CSRTT (the 
latter serving to reveal non-specific drug effects unrelated to antag-
onism of NK1R), we tested them using two different test parame-
ters: a prolonged inter-trial interval (long inter-trial interval (LITI) 
of 7 s) and a randomised, variable inter-trial interval (VITI) of 2 – 
15 s, during which animals were required to withhold their motor 
response. These two test conditions challenge the performance of 
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mice in the 5-CSRTT in different ways (Humby et al., 2005; Patel 
et al., 2006; Sanchez-Roige et al., 2012). In particular, in the VITI, 
it is not possible to predict when the light cue will appear after trial 
initiation, and so this test avoids the potential confound of animals 
using interval-timing to prompt their responses, which is thought 
to occur with the LITI (Praamstra et al., 2006; Sanchez-Roige 
et al., 2012). Because these two test conditions seem to reveal dif-
ferent performance deficits (Yan et al., 2011), we thought it advis-
able to test mice under both conditions.
We took into account that, in the course of testing the effects of 
a control vehicle and two drugs (each at two doses), the animals 
would be exposed repeatedly to the LITI and VITI tests. To inves-
tigate whether the animals’ baseline performance changes during 
repetition of the tests (Economidou et al., 2012), we monitored the 
behaviour of untreated animals (i.e. no injection of vehicle or 
drug) in two successive LITI and VITI tests (termed NI-1 and 
NI-2) and then, again, in a third LITI and VITI test (NI-3). This 
final test was incorporated into a counterbalanced series of tests of 
the animals’ performance after treatment with NK1R antagonists 
and vehicle.
Finally, results from our earlier study suggested that certain per-
formance scores in the 5-CSRTT, especially premature responses, 
depended on whether animals were tested in the morning or the 
afternoon (Yan et al., 2011). To explore this further and to ensure 
that this factor did not confound interpretation of our study results, 
the behavioural scores were again compared in different groups of 
mice that were tested at either of these times of day.
Materials and methods
Ethics statement
These experiments were licensed under the UK Animals (Scientific 
Procedures) Act of 1986, after ethical approval at University 
College London and the University of Sussex, UK (PPL number 
70/6837).
Animals
Male wild type (NK1R+/+) and NK1R-/- mice, with the same 
genetic background, were used (129/Sv x C57BL/6J, crossed 
with an outbred MF1 strain many generations ago (described 
fully in De Felipe et al., 1998). The colonies were bred at UCL in 
a facility held at 21 ± 2 °C, 45 ± 5% humidity, with a 12 h : 12 h 
light : dark cycle (where lighting increased gradually, from 07.00 
– 08.00 h).
Four mice were taken, at random, from three homozygous 
breeding pairs for each genotype. Littermates were housed 
together, such that every home cage contained up to four wild 
type or four NK1R-/- mice. The home cages incorporated envi-
ronmental enrichment and were cleaned twice a week. Water 
was freely available, but the food supply was adjusted to stabi-
lise each subject at 90% of free-feeding body weight. The sub-
jects weighed 25.7 – 37.2 g and were 6 – 8 weeks of age before 
the start of food restriction. They were brought into the labora-
tory at the same time every day (Monday to Friday, at 09:30 h) 
and weighed before training / testing in the 5-CSRTT. Two mice 
of each genotype, from each cage, were trained and tested in the 
morning (10.00 – 11.30 h: i.e. after 18 – 19h of food deprivation) 
while the remainder were trained and tested in the afternoon 
(13.00 – 14.30 h: i.e. after 21 – 22 h of food deprivation). All 
animals were returned to the housing facility at 16.00 h and pro-
vided with their quota of food. One wild-type mouse died during 
training.
Apparatus (5-CSRTT)
The 5-CSRTT apparatus (Med Associates, St. Albans, VT, USA) 
comprised four operant chambers with five equally-spaced aper-
tures incorporated in the rear wall: each of these holes could be 
illuminated independently. A magazine in the opposite wall deliv-
ered a liquid reward (0.01 mL of a 30% condensed milk solution). 
Interception of an infrared photo-cell beam scored mouse head-
entries into either the test holes or the magazine. The entire proce-
dure was controlled by a Smart Ctrl Package 8IN/16OUT with an 
additional interface, MED-PC for Windows (supplied by Med 
Associates, St. Albans, VT, USA). 
5-Choice Serial Reaction-Time Task
The procedure is based on that developed by Oliver et al. (2009) 
and is described fully in Yan et al. (2011). The schedule for train-
ing and testing of the mice is illustrated in Figure 1. Briefly, after 
habituation to the apparatus and training to baseline criterion at 
Stage 6, the mice were tested with a VITI of 2, 5, 10 or 15 s, in 
Figure 1. Chronology of the experimental protocol. The test treatments 
comprised: non-injected mice (NI-1 to NI-3); vehicle injection (Tween 80 in 
0.9% saline); L 733060 (5 or 10 mg/kg i.p.); RP 67580 (5 or 10 mg/kg i.p.).
i.p.: Intraperitoneal injection; LITI: long inter-trial interval; NI: non-injected; 
VITI: variable inter-trial interval.
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which the ITI was delivered on a random schedule (compared 
with a fixed interval of 5 s, at Stage 6). This was followed by a 
single test with a LITI in which the interval remained constant 
(7 s). After a premature response, omission, or incorrect response, 
the house-light was switched off for 5 s before starting the next 
trial. For each premature response, one additional trial was added 
to the series, to ensure that the performance of the mice was tested 
over a full complement of 100 trials. The testing sessions were 
first carried out on uninjected mice (i.e. no pre-treatment with 
either vehicle or test drug (no-injection 1: NI-1)). Mice were 
always tested on Friday. In between (Monday to Thursday), they 
were retrained to ensure that the criteria for baseline performance 
were restored, before retesting at the end of the week.
Stable baseline criteria (> 75% accuracy; < 25% omission 
errors, for at least 3 consecutive days) follow equation (1):
Total trials – premature responses = 100  (1)
After NI-1, a free-feeding diet was restored during a 1-week 
closure of the establishment. Animals’ body weight was reduced 
to 90% of their free-feeding weight over the next 2 weeks and then 
the criteria for baseline behavioural performance were restored 
over a 3-week period of retraining at Stage 6 (Figure 1). All the 
mice were then tested for a second time (with no vehicle or drug 
injection: NI-2) in the LITI and VITI.
One week after testing in NI-2, the mice started a final series 
of once-weekly tests. This incorporated a third session in which 
the mice were not injected with either vehicle or drug (NI-3), 
which was embedded within the series of counterbalanced, Latin-
square tests carried out 30 min after an intraperitoneal (i.p.) injec-
tion of either vehicle (10 mL/kg; Tween 80 in 0.9% saline), or 
RP 67580 (5 or 10 mg/kg; ‘RP-5 / RP-10’), or L 733060 (5 or 10 
mg/kg; ‘L-5 / L-10’). Inclusion of NI-3 within this sequence ena-
bled us to control for changes in baseline behavioural scores 
(including possible carry-over from a previous drug treatment) 
during this prolonged series of 5-CSRTT tests, and also to control 
for an interaction between the effects of the drugs and the injec-
tion procedure on behaviour. We chose these drug doses because 
they induced locomotor hyperactivity in wild type mice, in a pre-
vious study (Yan et al., 2009). Every mouse experienced each test 
(no treatment, vehicle, RP 67580 and L 733060 (each at 2 doses: 
5 mg/kg and 10 mg/kg)) in the LITI and VITI, only once (i.e. 12 
tests in all). Individual mice served as a blocking factor with the 
sequence of within-subject treatments counterbalanced across 
subjects.
Only two of the 24 mice did not complete the study. One died 
during training and one NK1R -/- did not complete all the tests for 
all drug doses. Sample numbers for each test condition are given 
in Table 1.
Behavioural scoring
The following performance variables in the 5-CSRTT tests were 
scored, with online capture and storage of the data:
● Total number of sessions required to pass the training 
phase: the sum of all the sessions completed over Stages 
1 – 6 of training.
● Total number of trials completed in each test session: 
total correct responses + total incorrect responses + total 
test (maximum = 100 or 45 min, whichever occurs first).
 Total trials per test session = Total correct + total incor-
rect + total omissions (2)
● % Accuracy = 
correct responses
(correct + incorrect responses) 
 1





 × 00
(3)
● Latency to correct response: latency to nose-poke into 
the correct hole after the onset of stimulus.
● Latency to collect the reward (reach the magazine): 
latency to collect the reinforcer after a correct response.
● % Omissions = 
 total omissions 
(correct + incorrect responses + omissions)
   100





 ×
(4)
● Perseveration score: The total number of responses (per 
100 trials) into the same, correct hole during the interval 
between a correct response and collection of the 
reinforcer.
● Premature responses: The number of premature 
responses (per 100 trials). An additional trial was added 
to the total after each premature response, to ensure that 
the animals would complete 100 trials.
Drugs and reagents
The NK1R antagonists, L 733060 ((2S,3S)-3-[(3,5-bis 
(Trifluoromethyl) phenyl) methoxy]-2-phenylpiperidine hydro-
chloride) and RP 67580 ((3aR,7aR)-Octahydro-2-[1-imino-
2-(2-methoxyphenyl) ethyl]-7,7-diphenyl-4H-isoindol) were 
purchased from Tocris and dissolved/ sonicated in 10 µL Tween 
80, with their final volumes adjusted for i.p. injection (10 mL/kg) 
with 0.9% sterile saline.
Statistics
The experiment adopted a counterbalanced block design with 
repeated measures. We used SPSS PC+ and InVivoStat (Clark et 
al., 2011) for statistical analysis of the data. If necessary, the raw 
data were transformed to ensure homogeneity of the variance in the 
Levene’s test for between-subject factors. Transforms were either:
The square-root of the behaviour score, or
Lg10 = Log10(behavioural score +1) (5)
or, for % accuracy:
arsin %accuracy = arsin
behaviour score
100








 (6)
The transformation that produced the data set with the most 
homogeneous variance was used in the ANOVA.
Table 1. Sample number for each fixed factor in the study.
Time of testing LITI VITI
wild type NK1R-/- wild type NK1R-/-
AM 6 6 6 6
PM 5 5 or 6 5 5 or 6
AM: a.m., i.e. before noon; LITI: fixed inter-trial interval; NK1R-/-: genetically-
altered mice, lacking functional NK1 receptors; PM: p.m., i.e. after noon; VITI: 
variable inter-trial interval 
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We assessed the effects of the main factors, or their interac-
tions, using 2-way repeated measures Analysis of Variance 
(ANOVA), with ‘genotype’ as a between-subjects factor and ‘test 
treatment’ (NI-3 / vehicle / dose of drug) as a within-subjects fac-
tor. The mouse-testing time (morning or afternoon) was treated as 
another between-subjects fixed factor. Mauchly’s test was used to 
confirm sphericity of the variance / covariance matrix for within-
subject factors. Because none was significant for any of the com-
parisons, no ε-correction was necessary. Data across the NI tests, 
using the LITI and VITI, were evaluated separately. We evaluated 
the drug effects from the data obtained from tests of vehicle versus 
the two drug doses. Results for each compound and the VITI and 
LITI tests were analysed separately. A significant effect of one of 
the main factors, or a relevant interaction between them, was taken 
as the criterion for progressing to 1-way ANOVA and post hoc 
multiple group comparisons, which used the Least Significant 
Difference (LSD) test. Changes in premature responses on repeated 
testing and after each drug treatment were also subjected to linear 
and quadratic regression analysis (across vehicle and the two drug 
doses) to calculate the best fit to the data and to estimate the regres-
sion parameters. Statistical significance was set at P < 0.05. 
Results
All mice from both genotypes passed stages 1 – 6 of training and 
satisfied the established criteria for stable baseline performance 
before testing in the LITI and VITI (see Equation (1); > 75% accu-
racy; < 25% omission errors) for at least 2 consecutive days, at 
stages 1 – 5, and for 3 consecutive days of stage 6 parameters.
As described in detail, below, when NK1R-/- mice experi-
enced either the LITI or VITI tests for the first time (NI-1), they 
expressed greater % omissions (and a longer latency to collect the 
reward) than the wild types. A higher incidence of premature 
responses, perseveration, and a longer latency to the correct 
response were also evident in the VITI test.
Genotype-dependent differences in behaviour 
of mice in the LITI and/or VITI tests 
depended on past experience of the tests
Premature responses declined overall, on repetition of the VITI test, 
but the pattern differed in the two genotypes (repetition*genotype: 
F (2, 36) = 9.6; P < 0.001), as seen in Figure 2a. Whereas NK1R-/- 
mice showed a progressive (linear) reduction in premature responses 
(F (1,10) = 22.8; P < 0.001), the response for the wild types was best 
fitted by a quadratic regression ((quadratic) F (2,30) = 4.45; P < 
0.01; P = 0.02, b1 = 0.908, b2 = –0.225; R2 = 0.229; (linear) F(1,31) 
= 0.04; P = 0.85; b1= 0.009, R2 = 0.001), with the incidence of pre-
mature responses in NI-2 being greater than in NI-1 (F(1,9) = 11.4; 
P < 0.01; post hoc LSD: P = 0.01) and NI-3 (P < 0.05).
By contrast, there was no overall difference in premature 
responses between the two genotypes, when tested in the LITI, 
and this did not change upon repetition of the test (Figure 2(b)). 
However, the incidence of this behaviour in the two genotypes 
depended on whether they were tested in the morning or afternoon 
(genotype *time of testing: F (1, 19) = 5.5; P < 0.05), with 
NK1R-/- mice showing a higher incidence in the afternoon, over-
all (F (1, 10) = 9.2; P < 0.05). Equivalent comparisons for the 
VITI test were not statistically significant.
Perseveration was exacerbated in both genotypes, overall, by 
repetition of the VITI (cf NI-1 and NI-3: F(2, 65) = 4.4; P < 0.01), 
as seen in Figure 2(c), and LITI (F(2,38) = 5.6; P < 0.01) in Figure 
2(d). In the VITI, there was a greater incidence of this behaviour 
in NK1R-/- mice than in the wild types (F (1, 18) = 6.0; P < 0.05) 
but, in the LITI, an apparent genotype difference just missed the 
criterion for statistical significance (F (1, 19) = 3.9; P = 0.06) 
(Figure 2(d)).
The % omissions was greater, overall, in NK1R-/- mice than 
wild types in the VITI (NI-1 – NI-3: F (2, 36) = 17.3; P < 0.001), 
as seen in Figure 3(a), and the LITI (NI-1 – NI-3, F (2, 38) = 7.93; 
P < 0.001) (Figure 3(b)); and it was unaffected by the time of test-
ing, but fell markedly (30 – 50%) in both genotypes, on repetition 
of either test (Figure 3(a) and Figure 3(b)).
There was a parallel, small reduction (4 – 15%) in the latency 
to correct response of both genotypes in the VITI: F(2,36) = 10.8; 
P < 0.001 (Figure 3(c)) and the LITI: F(2,38) = 5.89; P < 0.01 
(Figure 3(d)), and a slight overall improvement in % accuracy (2 
– 7%) in the VITI: F(2,36) = 17.9; P < 0.001 (Figure 3(e)), but 
none of these changes interacted with the genotype.
The only behaviour to be unaffected by repetition of either test 
was latency to collect the reward, which remained slightly greater 
in NK1R-/- mice, throughout (LITI: F (1, 19) = 6.1; P < 0.05; 
VITI: F (1, 18) = 12.1; P < 0.01), as seen in Figure 4.
NK1R antagonists modify the performance 
of both wild type and NK1R-/- mice in the 
5-CSRTT
Neither RP 67580 nor L 733060 affected the total number of trials 
(data not shown) or % accuracy (see Figure 6(a) and (b)) in either 
the LITI or the VITI which indicated that they had no actions that 
obstructed animals’ ability to carry out the test, or impaired their 
performance accuracy, once a cued response was initiated.
The effects of vehicle or drug treatments on premature 
responses in the VITI depended on genotype (treatment*genotype: 
F (3, 60) = 3.9; P < 0.05), but were unaffected by the time of test-
ing (Figure 5(a)). RP-10 reduced the incidence of this behaviour, 
compared with vehicle (F (2, 32 = 7.4; P = 0.01), but the reduction 
compared with response to RP-5 was even more consistent (LSD: 
P < 0.001). Moreover, the best fit to the response of wild types to 
the two doses of RP 67580 was a quadratic, rather than a linear, 
regression (F (2, 30) = 7.6; P < 0.01; b1 = 1.23, R2 = 0.34 versus 
(linear) F (1, 31) = 4.08; P = 0.052); b1 = – 0.14, b2 = – 0.34, R2 = 
0.116).
In the LITI, the premature responses depended on whether the 
mice were tested in the morning or afternoon (genotype * ‘time of 
testing’: F (1, 18) = 13.2; P < 0.01), as seen in Figure 5(b). 
L 733060 strongly affected premature responses of wild types 
tested in the morning. As with RP 67580, the response to L 733060, 
across vehicle and the two drug doses, was best described by a 
quadratic regression (F (2, 15) = 5.51; P < 0.05; b1 = 1.89, b2 = – 
0.51; R2 = 0.42), rather than linear regression F (1, 16 = 1.46; P = 
0.24, b1 = – 0.146, R2 = 0.08). Consistent with this, the incidence 
of premature responses after treatment with the L-10 dose was less 
than after L-5 (F (3, 23 = 5.39; P < 0.007; LSD: P < 0.01), but did 
not differ from vehicle. However, an apparent increase in prema-
ture responses after treatment with the L-5 dose just failed to reach 
the criterion for statistical significance (LSD: P = 0.06). Compared 
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with vehicle, the higher dose of RP 67580 (RP-10) also reduced 
premature responses in the wild types tested with the LITI in the 
morning (F (3, 23) = 8.24; P < 0.001; c.f. vehicle: LSD: P < 0.01), 
as seen in Figure 5(b), but the equivalent comparison for NK1R-/- 
mice just missed the criterion for significance (c.f. R-5 and R-10, 
LSD: P = 0.06).
As before, the incidence of perseveration in the VITI was 
higher in NK1R-/- mice than in the wild types, overall (F (1, 18) 
= 9.4 P < 0.01), but none of the drug treatments, nor the time of 
testing, affected this behaviour (Figure 5(c)). In the LITI, perse-
veration by NK1R-/- mice was again higher in the afternoon 
than the morning (genotype*time of testing’ LITI: F (1, 18) = 
4.5, P < 0.05), as seen in Figure 5(d), and was also higher in the 
NK1R-/- mice than in the wild types, overall (F (1, 8) = 6.8; P < 
0.05), but neither genotype was affected by either NK1R 
antagonist.
Compared with vehicle, the RP-10 dose increased % omissions 
(Figure 6(a) and Figure 6(b)), latency to correct response (Figure 
6(c) and Figure 6(d)); and latency to collect the reward (Figure 
6(e) and Figure 6(f)) of both genotypes, in the LITI and VITI tests. 
RP 67580 did not affect % accuracy (Figure 6(g) and Figure 6(h)), 
but after treatment with L 733060, there was a dose * genotype 
interaction in the LITI (F (2, 40) = 5.14; P < 0.01) (Figure 6(h)). 
Although NK1R-/- showed greater % accuracy than wild types at 
both doses (LSD: P < 0.001), the response did not differ from 
vehicle in either case.
Figure 2. Repeated testing with the VITI and LITI modified premature responses and perseveration. Bar charts indicate mean ± s.e.m. transformed 
scores (as applied in the statistical analysis) for uninjected mice tested for the first (NI-1), second (NI-2) and third (NI-3) time. The NI-3 test 
condition is embedded in the counterbalance series of tests of drug or vehicle, in the LITI and VITI, in which animals receive a total of 12 tests in 
all. Lines linking boxes (open or filled) indicate a difference across the clusters of test groups indicated, and solid lines link groups which differ at 
statistical significance of P < 0.05, at least. Premature responses in the VITI declined in NK1R-/- mice, but not wild types, and did not change in 
either genotype when tested repeatedly in the LITI. Perseveration increased in both genotypes, on repetition of either test. When mice were tested 
in the LITI in the afternoon, premature responses by NK1R-/- mice were greater than in wild-type mice were perseveration of the NK1R-/- mice was 
greater than when they were tested in the morning. For sample ‘N’, see Table 1.
AM: before noon;  Lg10: Log10 ; LITI: fixed intertrial interval ; NI: non-injected; NK1R-/-: genetically altered mice that lack functional NK1 receptors; PM: after noon; 
s.e.m.: standard error of the mean; VITI: variable intertrial interval.
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Discussion
The two genotypes reached the criteria for testing with the VITI 
and LITI, which confirmed that they were both able to learn the 
task to the standard baseline.
Behavioural deficits are attenuated by 
repeated experience of the LITI and VITI tests
NK1R-/- mice displayed greater % omissions, premature 
responses and perseveration than wild type mice, when tested in 
Figure 3. Repeated experience of the LITI and VITI tests reduced % omissions and latency to respond, and improved % accuracy, in the 5-CSRTT. 
Bars indicate mean ± s.e.m. transformed scores (as applied in the statistical analysis) for uninjected animals, when tested for the first (NI-1), 
second (NI-2) and third (NI-3) time. The NI-3 test condition is embedded in the counterbalanced series of tests of drug or vehicle in the LITI and 
VITI, in which animals received a total of 12 tests in all. Solid lines link test groups for which the statistical significance of differences is P < 0.05, 
at least. For sample ‘N’, see Table 1.
AM: a.m., i.e. before noon; arsin: arcsine; Lg10: Log10; LITI: fixed inter-trial interval; NI: non-injected; NK1R-/-: genetically-altered mice, lacking functional NK1 recep-
tors; PM: p.m., i.e. after noon; s.e.m.: standard error of the mean; sqrt: square-root; VITI: variable inter-trial interval.
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the 5-CSRTT for the first time; but in the LITI, there was a greater 
incidence of premature responses, only in the afternoon. Apart 
from the emergence of a longer latency to collect the reward in the 
VITI, all these findings support those reported in Yan et al., (2011) 
and Dudley et al. (2013). However, we now add the caveat that 
premature responses by NK1R-/- mice diminish, when they are 
tested repeatedly with the VITI.
There are strikingly few published studies involving repeated 
assessment of humans in Choice Reaction-Time Tests. Measures 
of inattention do seem to change (Castellanos et al., 2000; Kuntsi 
et al, 2005; Soreni et al., 2009), but no clear pattern has emerged 
so far. However, there are reports that premature responses by out-
bred (wild type) Lister hooded rats do not change on repetition of 
the LITI (Besson et al., 2010), as was found here with our mice. 
By contrast, repetition of the VITI test does reduce premature 
responses by inbred C57BL/6J mice (Walker et al., 2011), as was 
also found here in the NK1R-/- strain. The transient increase in 
premature responses in NI-2, when wild types were tested in the 
VITI, could arise from the pause between testing in NI-1 and 
NI-2; but, if so, it remains to be explained why this did not happen 
in the LITI or in NK1R-/- mice, as well.
Further changes were a reduction in % omissions and an 
increase in perseveration in both genotypes, on repetition of the 
LITI and the VITI tests. Neither can be explained by a reduction 
in motivation to carry out the task, because latency to correct 
response was reduced, and latency to reward was unaffected, in 
both tests. Instead, it seems that animals learned to improve their 
performance, as they do in a 5-hole operant gambling task (Young 
et al., 2011), and this is evident even within the training sessions. 
Whether there are within-session genotype differences in learning 
that could explain why premature responses in the VITI only 
diminished in NK1R-/- mice, will be explored in the future. 
Nevertheless, ‘learning’ cannot explain why perseveration was 
exacerbated in both genotypes, in both tests.
The reduction in % omissions and premature responses and the 
increase in perseveration all occurred in both genotypes, so the 
underlying mechanism(s) cannot involve NK1R. However,  noradr-
energic, serotonergic and dopaminergic transmission are all strong 
candidates. First, as discussed in detail in Yan et al. (2011), these 
monoamine transmitters modulate attention (Aston-Jones and 
Cohen, 2005), impulsivity (Cole and Robbins, 1987; Dalley and 
Roiser, 2012) and perseveration (Pioli et al., 2008). Secondly, their 
release is abnormal in NK1R-/- mice (Fisher et al, 2007; Froger et 
al., 2001; Herpfer et al., 2005). Thirdly, monoaminergic adaptation 
to challenging stimuli is well-known (e.g. Stanford, 1995). Lastly, 
drugs that augment monoaminergic transmission relieve behav-
ioural deficits in ADHD (Heal et al., 2012). Indeed, a study which 
combined microdialysis with the 5-CSRTT confirms that noradren-
aline efflux in the prefrontal cortex does not change during perfor-
mance of the 5-CSRTT, but does increase in response to task 
challenges such as a change in the predictability of the light cue 
(Dalley et al., 2001).
We cannot distinguish why premature responses in the LITI 
depended on the time of testing, but NK1R-mediated regulation of 
circadian rhythms is a possibility (Piggins et al., 2001). Cognitive 
and motor activity both show circadian variation (Beau, 1992; 
Weinert and Waterhouse, 1998; Winocur and Hasher, 2004). 
Moreover, this rhythm is abnormal in the Spontaneously 
Hypertensive Rat (SHR), the established rodent model of ADHD 
(Adriani et al., 2003), and in ADHD patients (Chiang et al., 2010). 
In view of the findings discussed below, it is interesting that 
L-type Ca2+v channels are under circadian control (e.g. Colwell, 
2011; Ko et al., 2009; 2012; Nahm et al., 2005) and that the SHR 
and their WKY counterparts express different splice variants of 
these channels (Tang et al., 2008). Nevertheless, we cannot rule 
out the possibility that procedural factor(s) account for the differ-
ences in behaviour in mice tested in the morning or afternoon. 
One possibility is that the time of testing affects animals’ interval-
timing and, as a consequence, performance in Choice-Reaction 
Time tests (Sanchez-Roige et al., 2012; Smith et al., 2002). 
Interval-timing is under strong circadian control (Agostino et al., 
2011) but it is also disrupted in sleep-deprived subjects (Spati 
et al., 2009), which could be an important factor in this study, 
because the mice were tested during the light-phase. The differ-
ences are unlikely to be related to the time elapsed since animals 
were last fed, because that would be expected to reduce latency to 
respond and latency to collect the reward, and yet these measures 
did not differ in the morning and afternoon. Whatever the expla-
nation, we believe that this important finding, together with the 
dissociation of this behaviour in the LITI and VITI, merits further 
investigation in future studies, because it clearly affects the ani-
mals’ performance, so it should be a factor incorporated into the 
experimental design.
Figure 4. Latency to collect reward was unaffected by repetition of 
either the VITI or the LITI in either genotype. Bars indicate mean ± 
s.e.m. transformed scores (as applied in the statistical analysis). Solid 
lines link groups for which the statistical significance of the genotype 
difference is P < 0.05, at least. For sample ‘N’, see Table 1.
LITI: fixed inter-trial interval; NI: non-injected; s.e.m.: standard error of 
the mean; VITI: variable inter-trial interval.
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NK1R antagonists disrupt behaviour of  
wild type and NK1R-/- mice in the 5-CSRTT
Prompted by our findings that both L 733060 and RP 67580 
increase the locomotor activity of wild type mice (Yan et al., 
2010), and that % omissions, premature responses and persevera-
tion are exacerbated by a lack of functional NK1R in NK1R-/- 
mice (Yan et al., 2011), we predicted that these behaviours would 
also be increased in  wild type mice by treatment with these two 
drugs. Indeed, an increase in motor activity could exacerbate (or 
even underlie) any impairment of the animals’ performance in this 
test, as in ADHD patients. However, both drugs had complex 
effects on cognitive performance, most likely because their 
actions are not limited to NK1R antagonism. It should also be 
borne in mind that epigenetic or developmental changes could 
influence the behaviour of inbred homozygote mice, through the 
lifelong lack of NK1R in the breeding pairs and their progeny. 
Spontaneous mutation(s) in wild type and/or NK1R-/- mice are 
also possible. Nevertheless, acute antagonism of NK1R does 
increase locomotor activity of the wild types (Yan et al., 2010) and 
so this behaviour, at least, is not affected by such confounding 
influences.
Figure 5. The effect of RP 67580 and L 733060 on % premature responses depended on test procedure (LITI or VITI) and, in the LITI, depended on 
the time of testing (morning (AM) or afternoon (PM). Bars indicate mean ± s.e.m. transformed scores (as applied in the statistical analysis). All test 
conditions (NI-3, vehicle and both drugs at two doses) were carried out in a sequence defined by a William’s (counterbalanced) Latin square. Lines 
linking boxes (open or filled) indicate a genotype difference across the cluster of test groups indicated; and solid lines link groups which differ at 
a statistical significance of P < 0.05, at least. RP-5 increased premature responses in the VITI, but this increase was not evident at the higher dose. 
Similarly, premature responses after treatment with L-5 were greater than after L-10, and lower after RP-10 than RP-5 in both wild types tested in the 
morning and NK1R-/- mice tested in the afternoon. Perseveration was unaffected by either NK1R antagonist in either test. For sample ‘N’, see Table 1.
AM: a.m., i.e. before noon; L-5 and L-10: the dosage levels of drug L 733060; Lg10: log10; LITI: fixed inter-trial interval; NI: non-injected; NK1R-/-: genetically-altered 
mice, lacking functional NK1 receptors; PM: p.m. i.e. after noon; R-5 and R-10: the dosage levels of drug RP 67580; VEH: vehicle; VITI: variable inter-trial interval.
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Figure 6. RP 67580 (10 mg/kg) increased % omissions, latency to correct response and latency to collect the reward in both genotypes, in both 
the VITI (left column) and LITI (right) tests. Neither dose of L 733060 affected these behaviours. Bars indicate mean ± s.e.m. transformed scores 
(as applied in the statistical analysis). All test conditions (NI-3, vehicle and both drugs at two doses) were carried out in a sequence defined by 
a William’s (counterbalanced) Latin square. Solid lines link test groups for which the statistical significance of group differences is at P < 0.05, at 
least. For sample ‘N’, see Table 1.
AM: a.m. or before noon; arsin: arcsine; L-5 and L-10: the dosage levels of drug L 733060;  Lg10: log10; LITI: fixed inter-trial interval; NI: non-injected; NK1R-/-: 
genetically-altered mice, lacking functional NK1 receptors; PM: p.m. or after noon; R-5 and R-10: the dosage levels of drug RP 67580; s.e.m.: standard error of the mean; 
sqrt:  square-root; VEH: vehicle; VITI: variable inter-trial interval. 
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RP-10 increased % omissions in both genotypes, which indi-
cated a drug-induced increase in inattentiveness. Although latency 
to correct response and latency to collect the reward also 
increased, it is unlikely that the increase in % omissions was 
caused by either sedation or reduced motivation to respond, 
because neither drug affected the total number of trials completed 
or perseveration. Also, this drug dose increased locomotor activ-
ity in our previous study (Yan et al., 2010), an action that is not 
consistent with sedation; and sedation has not been reported by 
patients treated with the antiemetic NK1R antagonist, Apripetant. 
Nevertheless, the increased % omissions occurred in both geno-
types, so they cannot be attributed to NK1R antagonism.
Contrary to our prediction, RP-10 reduced premature responses 
in wild type mice. However, this reduction was more consistent 
when compared with the response to RP-5, rather than for vehicle, 
which could suggest that RP-5 exacerbated this behaviour, 
whereas the higher dose reduced it. This possibility is supported 
by the quadratic regression fit to the data for dose versus response. 
There was a similar (quadratic) response to L 733060, when wild-
type mice were tested in the LITI in the morning.
It is certain that the drug effects are not explained by any 
change in motivation to respond, because:
1. There was no change in the latency to respond or latency 
to collect the reward;
2. Unlike premature responses, neither of these latencies 
was affected by time of testing;
3. There was no change in % omissions; and
4. There was no reduction in the number of trials completed 
by the mice.
However, it remains to be explained why L 733060 did not 
affect premature responses, when wild type mice were tested in 
the afternoon.
Recently, we reported that the L-type Ca2+v channel blocker, 
nifedipine, increased % omissions and reduced premature 
responses in both genotypes (Dudley et al., 2012). Many, if not all, 
NK1R antagonists block L-type Ca2+v channels, which can con-
found the effects of NK1R antagonism on behaviour (Garret et al., 
1991; Guard et al., 1993; Rupniak et al., 1993; Seabrook et al., 
1996). It follows that a possible explanation for the complex 
effects of the two NK1R antagonists on premature responses in 
this study is that they are exacerbated by NK1R antagonism at low 
drug doses, and that this increase is masked by L-type channel 
blockade at higher doses. If so, our finding that both doses of 
NK1R antagonists induced hyperactivity in wild type mice, but 
had no effect on the hyperactive NK1R-/- mice (Yan et al., 2009), 
implies that L-channel blockade by NK1R antagonists does not 
affect locomotor activity. This proposal is consistent with reports 
that nifedipine does not affect spontaneous locomotor activity in 
the mouse (Maiolini et al., 2003; Zhang et al., 1994).
Neither antagonist affected perseveration, which could sug-
gest that this behaviour arises from a lifelong deficit in NK1R. 
Alternatively, NK1R occupancy by these antagonists was insuffi-
cient to modify behaviour. The latter is more likely, because the 
L-type channel blocker, nifedipine, did increase preservation in 
the VITI (Dudley et al., 2012), and RP 67580 is a comparatively 
weak L-type channel blocker (c.f. Murphy et al., 1990; Rupniak et 
al., 1993). To the best of our knowledge, the binding affinity of 
L 733060 to L-type channels has not been evaluated.
We cannot be certain about the explanation for the differences in 
the effects of the two antagonists on premature and perseverative 
responses in the LITI and the VITI. However, our findings suggest 
that RP 67580 has a higher affinity for L-type channels than does 
L 733060, so it is more likely to mask any effects of NK1R antago-
nism on these behaviours. These pharmacological differences will 
be complemented by any differences in the influence of NK1R and 
L-type channels in the neuronal pathways that mediate these 
behaviours.
There was a small increase in % accuracy when NK1R-/- were 
tested in the LITI after treatment with L 733060, but no other test 
nor treatment condition affected this measure. This finding reflects 
the lack of any consistent evidence for impaired task accuracy in 
ADHD patients (Epstein et al., 2011) and also the lack of any 
beneficial effects of drugs used to treat this disorder (Koffarnus 
and Katz, 2011; Prasad et al., 2012).
In conclusion, the test experience and/or time of testing 
affected measures of performance of mice in the 5-CSRTT, 
which is likely to be relevant to assessments of ADHD patients 
(Kuntsi and Klein, 2012). As well as being influenced by these 
factors, the effects of NK1R antagonists are confounded by their 
lack of selectivity for NK1R. As in preclinical screens for anti-
depressants (Rupniak et al., 1993), the complex actions of NK1R 
antagonists need to be taken into account when assessing their 
effects on cognitive performance in the 5-CSRTT and other 
behaviours.
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